1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Citi notes that investor confidence for Telix Pharmaceuticals hinges on the resubmission of a brain cancer imaging agent to the US FDA...
Citi believes that approval will be granted in the second half of this financial year...
In the insurance space... multiple brokers have cut their target prices on QBE and Suncorp...
UBS and Citi both underline that Suncorp's catastrophe costs so far this year sit above their first-half allowance.
On Thursday, Suncorp flagged higher costs following storms in Queensland and New South Wales.
Citi has cut its target price on Suncorp to $19.25, while UBS cut its price to $22.
Both investment firms prefer IAG among domestic insurers, saying Suncorp remains too exposed to catastrophe costs.
Elsewhere - Jefferies has flagged that BlueScope's new electric smelting furnace may not add production value, but that it could cut costs.
The broker has kept its 'buy' call, with a $28 price target.
